NCT02613988

Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas

Early Response Assessment Using on 3T Advanced MR Imaging as Predictor of Long-term Treatment Response in Newly Diagnosed Glioblastomas

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial studies advanced MR imaging techniques in measuring early response of standard treatment may become predictors of long-term treatment response in patients with newly diagnosed glioblastomas.

Detailed description

The standard care of patients with glioblastoma is concomitant chemoradiation and adjuvant temozolomide. Allowing for assessment of tumor therapy prior to treatment completion is important to select patients most likely to benefit from alternative treatment option. Multimodal advanced MR imaging- contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, chemical exchange saturation transfer imaging, and perfusion imaging on 3T enables quantitative assessment of treatment response. Quantifying changes in advanced MR imaging techniques would allow predict outcome for early and long-term treatment response and survival in glioblastomas.

Conditions

• Adult Glioblastoma

Interventions

Type	Name	Description
DEVICE	3 Tesla magnetic resonance imaging	High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
DEVICE	Chemical exchange saturation transfer MRI	Amide proton transfer-weighted image
DEVICE	Diffusion weighted MRI	diffusion-weighted image with b value 0, 1000, and 3000
DEVICE	Dynamic susceptibility contrast MRI	dual echo EPI sequence

Timeline

• Start date: 2020-01-12
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2015-11-25
• Last updated: 2024-05-14

Locations

1 site across 1 country: South Korea